Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.40 |
| ▸ | CA5A | P35218 | 7/20 | 0.40 |
| ▸ | CA7 | P43166 | 7/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.40 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 4/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10869347 | 0.84 | CA1 (0.43) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL5679972 | 0.78 | CISD1 (0.37) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL30505689 | 0.78 | CYP2C9 (0.50) | CYP2C9KDM4ETAAR1KMT2AMEN1 | |
| SCHEMBL17388884 | 0.77 | MEN1 (0.47) | CYP2C9KMT2AMEN1CTDSP1NSD2 | |
| SCHEMBL7001903 | 0.77 | NPC1 (0.54) | CYP2C9L3MBTL1TAAR1KMT2APOLB | |
| SCHEMBL2398615 | 0.76 | SLC6A3 (0.39) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL10622914 | 0.73 | HTT (0.50) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL1875471 | 0.73 | CA2 (0.40) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL5679966 | 0.73 | CA2 (0.39) | CYP2C9CA1CA2CA5ACA7 | |
| SCHEMBL11823652 | 0.73 | HSPA5 (0.58) | CYP2C9L3MBTL1TAAR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107820429-B | Novel compositions and methods for immunotherapy comprising small molecule integrin receptor-ligand agonist adjuvants | 7山药物有限责任公司 | 2022-08-16 | — | — | CN | disclosed |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | 7 HILLS PHARMA INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3288585-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS, LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-3164127-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3104867-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS INTERESTS, LLC (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016176400-A2 | NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS | 7 HILLS INTERESTS LLC (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016003980-A1 | COMPOSITIONS AND METHODS TO IMPROVE ADOPTIVE CELL THERAPIES | 7 HILLS INTERESTS LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015123447-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS | 7 HILLS PHARMA, LLC (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | NEITZEL MARTIN | 2011-09-01 | — | — | US | disclosed |
| US-7939657-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | CYP2C9 1239/4885CA1 839/4885CA2 3100/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | CYP2C9 1069/4885CA1 591/4885CA2 3239/4885 |
| US-20210145796-A1 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | ITGB7, ITGA1, ITGAL | CYP2C9 4230/4885CA1 3374/4885CA2 4008/4885 |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | CYP2C9 1069/4885CA1 591/4885CA2 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.